Tracking inflammation changes during immunotherapy in gynecologic cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial looks at how a blood inflammation marker (CRP) changes when people with metastatic gynecologic cancers receive immunotherapy, sometimes together with palliative chemotherapy. The goal is to see patterns that may help doctors better understand and manage treatment responses to immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older
- You have confirmed metastatic (stage spread) gynecologic cancer based on biopsy/tissue testing
- You have a situation where doctors can use immune checkpoint inhibitor (immunotherapy) as part of treatment (in the study’s experimental group)
- You plan to receive immunotherapy combined with palliative chemotherapy in the experimental group
- If you are in the control group: you are receiving chemotherapy without immunotherapy in the first treatment line
- You can sign written informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well immunotherapy works for advanced or recurrent endometrial and cervical cancer by checking certain markers in your blood and tissue. It aims to find out which patients might benefit most from this treatment.
This study looks at how the bacteria in your gut might affect how well immunotherapy works for certain cancers. It is for people with advanced lung cancer, melanoma, or certain gynecologic cancers who are about to start immunotherapy, and it may help doctors understand why some people respond better than others.
This study looks at why some people with endometrial cancer respond well to immunotherapy. It uses samples of your tumor to help doctors better understand how to choose the right treatment for each person.
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
This study looks at how well a special blood test can detect certain immunotherapy drugs in your body. By measuring these drugs, doctors hope to better understand how the treatment is working for gynecological cancers and personalize care.
This study looks for new markers in the blood or tumor that could predict how well immunotherapies work for advanced digestive and gynecological cancers. It includes people getting immunotherapy, chemotherapy, or targeted therapy, and also those with certain liver or abdominal metastases that can be surgically removed after chemo.
Hear when a new Gynecological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.